Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment

NCT07228442 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT07228442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
February 28, 2031
Enrollment
92 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cutaneous squamous cell carcinoma